Reducing gun violence by increasing access to mental health services may cost billions of taxpayer dollars and give drugmakers that help treat mental illness a revenue windfall. But will it reduce gun violence? The answer is uncertain.

In the wake of the tragic shooting at Sandy Hook Elementary School, there have been repeated calls to increase access to mental health services as a way to reduce gun violence in the U.S., even though the evidence is weak at best that those services actually reduce gun violence.

Absent from these calls to action is any sense of how much that policy would cost. Many argue that any cost is worthwhile if it prevents just one needless death due to gun violence. But we live in austere fiscal times and knowing the price tag before taking action makes sense (click on the image above to enlarge).

A just-published Bloomberg Government Study estimates that the potential impact on the federal deficit due to increased spending on mental health services could exceed $260 billion from 2014 to 2021.

While the deficit could climb, this spending represents a major business opportunity for companies that make antidepressant and antipsychotic drugs. According to the study, if the percentage of people with a mental illness receiving care increased from the current level of 40 percent to 70 percent, then sales for the top 10 makers of drugs that treat mental illness would have seen revenue climb in 2012 from about $33 billion to more than $58 billion.

The policy question then becomes: what’s the goal of more mental health spending? Higher deficits, more money for drugmakers, or reducing gun violence? If it’s the latter, Congress and the president may want to rethink their approach, given the lack of evidence of its efficacy.

Matt Barry is the health analyst team leader for Bloomberg Government. This post first appeared on Bloomberg Government’s Blog.

Share on Twitter

2 Responses for “Drugmakers May Win Big in Effort to Curb Gun Violence”

  1. John Ballard says:

    What a curious approach to gun violence, approaching the problem via medication.
    Inasmuch as suicide gun deaths outnumber homicides (and most mental health experts agree that suicidal impulses are transitory) the pharmaceutical approach is like attacking poison ivy with calamine lotion instead of eliminating the plants.

    Who knows? A reduction in homicides may be a happy side effect.

  2. I believe the pharmacy companies are gouging everone for Humira, and scalara the prices are overpriced. I for one cannot afford to have it because of the expence 750.00 every two weeks. Not only the phrmacy but Humanna insurance compay, they do not help you at all. I will never have Humanna again and I hope no one else does either

Leave a Reply

FROM THE VAULT

The Power of Small Why Doctors Shouldn't Be Healers Big Data in Healthcare. Good or Evil? Depends on the Dollars. California's Proposition 46 Narrow Networking

Masthead

Matthew Holt
Founder & Publisher

John Irvine
Executive Editor

Jonathan Halvorson
Editor

Alex Epstein
Director of Digital Media

Munia Mitra, MD
Chief Medical Officer

Vikram Khanna
Editor-At-Large, Wellness

Joe Flower
Contributing Editor

Michael Millenson
Contributing Editor

We're looking for bloggers. Send us your posts.

If you've had a recent experience with the U.S. health care system, either for good or bad, that you want the world to know about, tell us.

Have a good health care story you think we should know about? Send story ideas and tips to editor@thehealthcareblog.com.

ADVERTISE

Want to reach an insider audience of healthcare insiders and industry observers? THCB reaches 500,000 movers and shakers. Find out about advertising options here.

Questions on reprints, permissions and syndication to ad_sales@thehealthcareblog.com.

THCB CLASSIFIEDS

Reach a super targeted healthcare audience with your text ad. Target physicians, health plan execs, health IT and other groups with your message.
ad_sales@thehealthcareblog.com

ADVERTISEMENT

Log in - Powered by WordPress.